[go: up one dir, main page]

WO2016050134A1 - 一种钠-葡萄糖协同转运蛋白2抑制剂的l-脯氨酸复合物、其一水合物及晶体 - Google Patents

一种钠-葡萄糖协同转运蛋白2抑制剂的l-脯氨酸复合物、其一水合物及晶体 Download PDF

Info

Publication number
WO2016050134A1
WO2016050134A1 PCT/CN2015/089128 CN2015089128W WO2016050134A1 WO 2016050134 A1 WO2016050134 A1 WO 2016050134A1 CN 2015089128 W CN2015089128 W CN 2015089128W WO 2016050134 A1 WO2016050134 A1 WO 2016050134A1
Authority
WO
WIPO (PCT)
Prior art keywords
ethanol
water
solvent
formula
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2015/089128
Other languages
English (en)
French (fr)
Inventor
孙飘扬
武乖利
郭昌山
卢韵
吴玉霞
沈灵佳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Priority to JP2017512686A priority Critical patent/JP6761564B2/ja
Priority to US15/514,118 priority patent/US10301344B2/en
Priority to BR112017005454A priority patent/BR112017005454A2/pt
Priority to EP15846001.4A priority patent/EP3202772B1/en
Priority to KR1020177009290A priority patent/KR20170060035A/ko
Priority to ES15846001T priority patent/ES2836099T3/es
Priority to CA2961819A priority patent/CA2961819C/en
Priority to CN201580008497.4A priority patent/CN105992769B/zh
Priority to PL15846001.4T priority patent/PL3202772T3/pl
Publication of WO2016050134A1 publication Critical patent/WO2016050134A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04—Cyclic acetals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present invention relates to 1,6-anhydro-1-C- ⁇ 4-chloro-3-[(3-fluoro-4-ethoxyphenyl)methyl]phenyl ⁇ -5-C-(hydroxymethyl)- ⁇ -L-idulonose L-proline complex, its monohydrate form and its A crystal form.
  • SGLT-2 sodium-glucose transporter 2
  • SGLT-2 was chosen as a target, both because of its absolute reabsorption of glucose and because it is only expressed in the kidneys.
  • the current study also found that the mechanism of action of SGLT-2 does not depend on the degree of dysfunction or insulin resistance of beta cells, and its effect does not decrease with the failure of beta cell function or severe insulin resistance. Therefore, there is reason to believe that SGLT-2 inhibitors have good prospects for the current treatment of type 2 diabetes.
  • WO2012019496 discloses an SGLT-2 inhibitor represented by the formula: 1,6-anhydro-1-C- ⁇ 4-chloro-3-[(3-fluoro-4-ethoxyphenyl) Methyl]phenyl ⁇ -5-C-(hydroxymethyl)- ⁇ -L-idulonose.
  • the crystal structure of the medicinal active ingredient often affects the chemical stability of the drug, and the difference in crystallization conditions and storage conditions may lead to changes in the crystal structure of the compound, sometimes accompanied by the formation of other forms of crystal form.
  • amorphous drug products have no regular crystal structure and often have other defects, such as poor product stability, fine crystallization, difficult filtration, easy agglomeration, and poor fluidity. Therefore, it is necessary to improve the various properties of the above products, and we need to study in depth to find new crystal forms with higher crystal purity and good chemical stability.
  • the present invention provides 1,6-anhydro-1-C- ⁇ 4-chloro-3-[(3-fluoro-4-ethoxyphenyl)methyl]phenyl ⁇ -5-C-(hydroxymethyl)
  • An L-proline complex of ⁇ -L-idulonose (as shown in formula (I)),
  • the complex of formula (I) may be 1,6-anhydro-1-C- ⁇ 4-chloro-3-[(3-fluoro-4-ethoxyphenyl)methyl]phenyl ⁇ -5-C- (Hydroxymethyl)- ⁇ -L-idulonose and L-valine co-crystallized.
  • the present invention provides a process for the preparation of the complex of formula (I), which comprises 1,6-anhydro-1-C- ⁇ 4-chloro-3-[(3-fluoro-4-ethoxyphenyl)methyl a step of co-crystallizing phenyl ⁇ -5-C-(hydroxymethyl)- ⁇ -L-idulonose and L-valine, wherein the co-crystallization step is carried out by adding L-valine and 1,6-anhydro-1-C- ⁇ 4-chloro-3-[(3-fluoro-4-ethoxyphenyl)methyl]phenyl ⁇ -5-C-(hydroxymethyl)- ⁇ -L - the molar ratio of iduropyranose is less than 2:1, preferably 2:1 to 0.1:1, more preferably 1.5:1 to 0.5:1, most preferably 1.5:1 to 1:1 or 1.2:1 to 0.8:1 .
  • the complex of formula (I) is relative to 1,6-anhydro-1-C- ⁇ 4-chloro-3-[(3-fluoro-4-ethoxyphenyl)methyl]phenyl ⁇ -5-C -(Hydroxymethyl)- ⁇ -L-idulonose has an increased melting point and improved stability.
  • Another aspect of the invention provides a monohydrate of the complex of formula (I) and a crystalline form thereof.
  • the X-ray powder diffraction pattern is represented by 5.50 (16.07), 7.82 (11.30), 8.64 (10.22), 10.33 (8.55), 12.18 (7.26), 12.49 (7.08), 14.47 (6.11), 15.51 (5.71). , 15.89 (5.57), 17.28 (5.13), 18.89 (4.70), 19.39 (4.58), 20.40 (4.35), 22.85 (3.89), 23.89 (3.72), 25.93 (3.43), 27.66 (3.22), 28.97 (3.08) And 31.16 (2.87) have characteristic peaks.
  • the invention also provides the preparation of 1,6-anhydro-1-C- ⁇ 4-chloro-3-[(3-fluoro-4-ethoxyphenyl)methyl]phenyl ⁇ -5-C-(hydroxyl)
  • the molar ratio of 5-C-(hydroxymethyl)- ⁇ -L-idulonose is less than 2:1, more preferably 2:1 to 0.1:1, further preferably 1.5:1 to 0.5:1, most preferably 1.5 : 1 to 1:1 or 1.2:1 to 0.8:1.
  • the organic solvent is selected from any one of an alcohol, a ketone, and an ester having a carbon number of 3 or less; or one or more halogenated hydrocarbons having a carbon atom of 3 or less.
  • Mixed solvent is selected from the group consisting of methanol, ethanol, isopropanol; or methanol/water, ethanol/water, isopropanol/water, ethanol/n-hexane.
  • the most preferred single solvent is ethanol.
  • a preferred mixed organic solvent is a mixed solvent of ethanol/water, and the ratio of the two is not particularly limited. In a preferred embodiment of the present invention, the volume ratio of the two is 19:1.
  • the method of recrystallization is not particularly limited and can be carried out by a usual recrystallization operation method.
  • the composite represented by the starting material (I) can be slowly cooled and crystallized by heating in an organic solvent, and after completion of crystallization, it can be dried by filtration to obtain a desired crystal.
  • the crystals to be filtered are usually subjected to vacuum drying under reduced pressure at a temperature of about 20 to 60 ° C, preferably under normal temperature, to obtain an effect of removing the recrystallization solvent.
  • the crystal of the composite of the formula (I) obtained was subjected to a crystal form study by differential scanning calorimetry (DSC) and X-ray diffraction pattern measurement, and the solvent residue of the obtained crystal was examined.
  • DSC differential scanning calorimetry
  • the composite type A crystal of the formula (I) prepared according to the method of the present invention does not contain or contains only a low content of residual solvent, and meets the requirements of the national pharmacopoeia for the residual solvent of the pharmaceutical product, so that the crystal of the present invention can be It is preferably used as a pharmaceutically active ingredient.
  • the type A crystal of the composite of the formula (I) prepared by the present invention has significantly better stability under high temperature and high humidity conditions than the amorphous sample, and under the conditions of grinding, pressure and heat, the crystal form It has good stability and can meet the medicinal requirements of production, transportation and storage.
  • the production process is stable and repeatable and controllable, and can be adapted to industrial production.
  • Fig. 1 is an X-ray powder diffraction pattern of the complex type A crystal of the formula (I).
  • Figure 2 is a DSC pattern of the complex type A crystal of the formula (I).
  • Figure 3 is an X-ray powder diffraction pattern of the amorphous solid of the composite of formula (I).
  • Figure 4 is a DSC chart of the amorphous solid of the composite of formula (I).
  • Figure 5 shows the 1,6-anhydro-1-C- ⁇ 4-chloro-3-[(3-fluoro-4-ethoxyphenyl)methyl]phenyl ⁇ -5-C-(hydroxyl) obtained in Example 15.
  • Example 1 obtained 1,6-anhydro-1-C- ⁇ 4-chloro-3-[(3-fluoro-4-ethoxyphenyl)methyl]phenyl ⁇ -5-C-(hydroxyl) TGA spectrum of solids with a ratio of 1:2- ⁇ -L-idulonose to proline
  • Example 1 obtained 1,6-anhydro-1-C- ⁇ 4-chloro-3-[(3-fluoro-4-ethoxyphenyl)methyl]phenyl ⁇ -5-C-(hydroxyl) DSC spectrum of a solid with a 1:2 ratio of )- ⁇ -L-idulonose to proline
  • a white solid of the compound of the formula (I) was obtained in a yield of 88%.
  • the X-ray diffraction spectrum of the crystal sample is shown in Fig. 1.
  • the crystals are at about 5.41 (16.33), 7.69 (11.49), 10.22 (8.65), 12.04 (7.35), 12.46 (7.10), 14.42 (6.14), 17.30 (5.12), 18.79 (4.72), 19.38 (4.58), 20.24. (4.38), 22.73 (3.91), 24.58 (3.62), 27.55 (3.24), 28.82 (3.10) and 31.03 (2.88) have characteristic peaks.
  • the DSC spectrum is shown in Fig. 2, which has a melting endothermic peak of 111.20 ° C, and this crystal form is defined as the A crystal form.
  • Example 1 The type A crystal product obtained in Example 1 and the amorphous sample prepared in Example 4 were separately placed in an open position, and examined under illumination (4,500 Lux), heating (40 ° C, 60 ° C), and high humidity (RH 75%, Stability of the sample under RH90%) conditions.
  • the sampling time was 5 days and 10 days, and the purity of HPLC was shown in Table 1.
  • the DSC plot shows that the resulting solid has three endothermic peaks at 60.78 ° C, 69.79 ° C, and 105.90 ° C, suggesting that the material may be less stable and that degradation may occur at lower temperatures leading to the detachment of proline from the co-crystal.
  • the TGA plot shows that the loss of valine in the solid is 30.58% (1,6-anhydro-1-C- ⁇ 4-chloro-3-[(3-fluoro-4-ethoxyphenyl)methyl]phenyl)
  • the ratio of -5-C-(hydroxymethyl)- ⁇ -L-idulonose to L-valine is 1:2, the theoretical value is 33.4%).
  • the DSC plot shows that the resulting solid has three endothermic peaks at 59.55 ° C, 72.24 ° C, and 105.49 ° C, suggesting that the material may be less stable and may degrade at lower temperatures leading to the detachment of proline from the co-crystal.
  • the TGA plot shows that the loss of proline in the solid is 32.82% (1,6-anhydro-1-C- ⁇ 4-chloro-3-[(3-fluoro-4-ethoxyphenyl)methyl]phenyl) ⁇ -5-C-(hydroxymethyl)- ⁇ -L-idulonose has a theoretical value of 33.4%).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrane Compounds (AREA)

Abstract

提供一种钠-葡萄糖协同转运蛋白2抑制剂的L-脯氨酸复合物、其一水合物及晶体。具体地，提供1,6-脱水-1-C{4-氯-3-[(3-氟-4-乙氧苯基)甲基]苯基}-5-C-(羟甲基)-β-L-艾杜吡喃糖L-脯氨酸（式(I)复合物）、其一水合物、A型结晶及其制备方法。所得到式(I)复合物的A型结晶具备良好的化学稳定性和晶型稳定性，并且所用结晶溶剂低毒低残留，可更好地用于临床治疗。

Description

一种钠-葡萄糖协同转运蛋白2抑制剂的L-脯氨酸复合物、其一水合物及晶体 技术领域
本发明涉及1,6-脱水-1-C-{4-氯-3-[(3-氟-4-乙氧苯基)甲基]苯基}-5-C-(羟甲基)-β-L-艾杜吡喃糖L-脯氨酸复合物、其一水合物形式及其A晶型。
背景技术
随着社会经济的发展和物质生活水平的提高，全球范围内糖尿病患者急剧增长，糖尿病通常分为Ⅰ型糖尿病和Ⅱ型糖尿病两种，其中90％以上为Ⅱ型糖尿病。已上市的糖尿病药物的种类很多，但迄今为止，还没有哪种药物能够凭一己之力将Ⅱ型糖尿病患者的血糖水平长期保持在目标范围之内。近年来对糖尿病发病机制的深入研究，为Ⅱ型糖尿病的治疗提供了越来越多的途径，而钠-葡萄糖协同转运蛋白2(sodium-glucose transporter 2，SGLT-2)抑制剂的发现，为糖尿病的治疗提供了又一新的思路。SGLT-2抑制剂的治疗机制是通过选择性抑制SGLT-2的活性来降低血糖。选择SGLT-2作为靶点，一方面是因为它对葡萄糖的绝对重吸收作用，另一方面是因为它仅表达于肾脏。目前的研究还发现，SGLT-2的作用机制不依赖于β细胞的功能异常或胰岛素抵抗的程度，其效果也不会随着β细胞功能的衰竭或严重胰岛素抵抗而下降。因此，有理由认为SGLT-2抑制剂用于当前Ⅱ型糖尿病的治疗具有良好的前景。
WO2012019496公开了一种如下式所示的SGLT-2抑制剂，其化学名为1,6-脱水-1-C-{4-氯-3-[(3-氟-4-乙氧苯基)甲基]苯基}-5-C-(羟甲基)-β-L-艾杜吡喃糖。
Figure PCTCN2015089128-appb-000001
然而直接将1,6-脱水-1-C-{4-氯-3-[(3-氟-4-乙氧苯基)甲基]苯 基}-5-C-(羟甲基)-β-L-艾杜吡喃糖作为药用活性成分是不现实的，因其熔点较低(83℃)，具有引湿性，开发形式欠佳，因此，将其改造成开发形式稳定的化合物具有十分重要的意义。
药用的活性成分的晶型结构往往影响到该药物的化学稳定性，结晶条件及储存条件的不同有可能导致化合物的晶型结构的变化，有时还会伴随着产生其他形态的晶型。一般来说，无定型的药物产品没有规则的晶型结构，往往具有其它缺陷，比如产物稳定性较差，析晶较细，过滤较难，易结块，流动性差等。因此，改善上述产物的各方面性质是很有必要的，我们需要深入研究找到晶型纯度较高并且具备良好化学稳定性的新晶型。
发明内容
本发明提供了1,6-脱水-1-C-{4-氯-3-[(3-氟-4-乙氧苯基)甲基]苯基}-5-C-(羟甲基)-β-L-艾杜吡喃糖的L-脯氨酸复合物(如式(I)所示)，
Figure PCTCN2015089128-appb-000002
式(I)所示复合物可由1,6-脱水-1-C-{4-氯-3-[(3-氟-4-乙氧苯基)甲基]苯基}-5-C-(羟甲基)-β-L-艾杜吡喃糖和L-脯氨酸共结晶得到。本发明提供了式(I)所示复合物的制备方法，包括将1，6-脱水-1-C-{4-氯-3-[(3-氟-4-乙氧苯基)甲基]苯基}-5-C-(羟甲基)-β-L-艾杜吡喃糖和L-脯氨酸共结晶的步骤，其中，所述共结晶步骤加入的L-脯氨酸和1，6-脱水-1-C-{4-氯-3-[(3-氟-4-乙氧苯基)甲基]苯基}-5-C-(羟甲基)-β-L-艾杜吡喃糖的摩尔比例小于2：1，优选2：1至0.1：1，更优选1.5：1至0.5：1，最优选1.5：1至1：1或1.2：1至0.8：1。
式(I)所示复合物相对于1,6-脱水-1-C-{4-氯-3-[(3-氟-4-乙氧苯基)甲基]苯基}-5-C-(羟甲基)-β-L-艾杜吡喃糖来说，熔点提高，稳定性提高。
本发明另一方面提供了式(I)所示复合物的一水合物及其A晶型。
式(I)所示复合物在不同结晶条件下得到的一系列结晶产物，对 所得结晶产物进行了X-衍射及DSC检测，发现式(I)所示复合物在常规的结晶条件下，可以得到一种稳定性良好的晶型，我们称其为A型结晶。本申请中的A型结晶的DSC图谱显示在109.51℃附近有熔融吸热峰，X-射线粉末衍射图谱如图1所示，使用Cu-Ka辐射，以2θ角度和晶面间距(d值)表示的X-射线粉末衍射图谱，其中在5.50(16.07)，7.82(11.30)，8.64(10.22)，10.33(8.55)，12.18(7.26)，12.49(7.08)，14.47(6.11)，15.51(5.71)，15.89(5.57)，17.28(5.13)，18.89(4.70)，19.39(4.58)，20.40(4.35)，22.85(3.89)，23.89(3.72)，25.93(3.43)，27.66(3.22)，28.97(3.08)和31.16(2.87)有特征峰。
本发明还提供了制备1,6-脱水-1-C-{4-氯-3-[(3-氟-4-乙氧苯基)甲基]苯基}-5-C-(羟甲基)-β-L-艾杜吡喃糖L-脯氨酸一水合物A型结晶的方法，包括以下步骤：
(1)1)将1，6-脱水-1-C-{4-氯-3-[(3-氟-4-乙氧苯基)甲基]苯基}-5-C-(羟甲基)-β-L-艾杜吡喃糖和溶解于溶剂中，使反应液溶清，冷却，析晶，所述溶剂选自有机溶剂或有机溶剂与水的混合溶剂；所述有机溶剂选自碳原子数小于等于6的醇类、酮类、酯类、醚类、烷烃、腈类的任意一种或几种；
(2)过滤、洗涤、干燥；
优选在步骤1中加入的L-脯氨酸和1，6-脱水-1-C-{4-氯-3-[(3-氟-4-乙氧苯基)甲基]苯基}-5-C-(羟甲基)-β-L-艾杜吡喃糖的摩尔比例小于2：1，更优选2：1至0.1：1，进一步优选1.5：1至0.5：1，最优选1.5：1至1：1或1.2：1至0.8：1。
在本发明优选的实施方案中，有机溶剂选自碳原子数小于等于3的醇类、酮类、酯类的任意一种；或一种或几种与碳原子小于等于3的卤代烃的混合溶剂。进一步优选有机溶剂选自甲醇、乙醇、异丙醇；或甲醇/水、乙醇/水、异丙醇/水、乙醇/正己烷。
进一步地，最优选的单一溶剂为乙醇。
在本发明的一个实施方案中，优选的混合有机溶剂为乙醇/水的混合溶剂，二者比例没有特别限制，在本发明优选的实施方案中，二者体积比为19：1。
重结晶的方法没有特别限定，可以用通常的重结晶操作方法进行。 例如，可以用原料式(I)所示复合物在有机溶剂加热溶解后慢慢冷却析晶，结晶完成后，经过滤干燥，即可得到所需要的结晶。需特别说明的是，所滤取的结晶体通常在减压下，在20～60℃左右，优选在常温条件下进行减压真空干燥，就能达到去除重结晶溶剂的效果。
通过差示扫描热分析(DSC)、X-衍射图谱测定，对得到的式(I)所示复合物结晶体进行了晶型研究，同时对所得结晶的溶剂残留进行了检测。
按照本发明的方法制备的式(I)所示复合物A型结晶不含有或仅含有较低含量的残留溶剂，符合国家药典规定的有关医药产品残留溶剂的限量要求，因而本发明的结晶可以较好地作为医药活性成分使用。
经研究表明，本发明制备的式(I)所示复合物的A型结晶在高温、高湿的条件下稳定性显著好于无定型样品，且在研磨、压力和受热等条件下，晶型稳定性良好，能够满足生产运输储存的药用要求，生产工艺稳定可重复可控，能够适应于工业化生产。
附图说明
图1式(I)所示复合物A型结晶的X-射线粉末衍射图谱。
图2式(I)所示复合物A型结晶的DSC图谱。
图3式(I)所示复合物无定型固体的X-射线粉末衍射图谱。
图4式(I)所示复合物无定型固体的DSC图谱。
图5实施例15所得1,6-脱水-1-C-{4-氯-3-[(3-氟-4-乙氧苯基)甲基]苯基}-5-C-(羟甲基)-β-L-艾杜吡喃糖与脯氨酸比例为1：2的固体的DSC图谱
图6实施例15所得1,6-脱水-1-C-{4-氯-3-[(3-氟-4-乙氧苯基)甲基]苯基}-5-C-(羟甲基)-β-L-艾杜吡喃糖与脯氨酸比例为1：2的固体的TGA图谱
图7实施例16所得1,6-脱水-1-C-{4-氯-3-[(3-氟-4-乙氧苯基)甲基]苯基}-5-C-(羟甲基)-β-L-艾杜吡喃糖与脯氨酸比例为1：2的固体的DSC图谱
图8实施例16所得1,6-脱水-1-C-{4-氯-3-[(3-氟-4-乙氧苯基)甲基]苯基}-5-C-(羟甲基)-β-L-艾杜吡喃糖与脯氨酸比例为1：2的固体的TGA 图谱
具体实施方式
以下将结合实施例更详细地解释本发明，本发明的实施例仅用于说明本发明的技术方案，并非限定本发明的实质和范围。
实验所用的测试仪器
1、DSC谱
仪器型号：Mettler Toledo DSC 1 Staree System
吹扫气：氮气
升温速率：10.0℃/min
温度范围：40-200℃
2、X-射线衍射谱
仪器型号：Bruker D8 Focus X-射线粉末衍射仪
射线：单色Cu-Kα射线(λ＝1.5406)
扫描方式：θ/2θ，扫描范围：2-40°
电压：40KV，电流：40mA
实施例1
取(1.0g，2.2mmol)1,6-脱水-1-C-{4-氯-3-[(3-氟-4-乙氧苯基)甲基]苯基}-5-C-(羟甲基)-β-L-艾杜吡喃糖(按WO2012019496公开的方法制备)，于7.20g乙醇中，加毕，搅拌溶解。常温下加入L-脯氨酸(0.2786g，2.42mmol，1.1eq)，加毕，搅拌下升温回流反应10min，使反应液溶清，趁热过滤，滤液搅拌降至室温，有大量白色固体析出，放置过夜，过滤，干燥，得到式(I)所示复合物白色固体1.14g，收率88％。该结晶样品的X-射线衍射谱图见图1。该结晶在约5.41(16.33)，7.69(11.49)，10.22(8.65)，12.04(7.35)，12.46(7.10)，14.42(6.14)，17.30(5.12)，18.79(4.72)，19.38(4.58)，20.24(4.38)，22.73(3.91)，24.58(3.62)，27.55(3.24)，28.82(3.10)和31.03(2.88)处有特征峰。DSC谱图见图2，有熔融吸热峰111.20℃，将此晶型定义为A晶型。
实施例2
取(1.0g，2.2mmol)1,6-脱水-1-C-{4-氯-3-[(3-氟-4-乙氧苯基)甲基]苯基}-5-C-(羟甲基)-β-L-艾杜吡喃糖(按WO2012019496公开的方法制备)，于8ml甲醇/水(v：v＝1：1)中，加毕，搅拌溶解。常温下加入L-脯氨酸(0.38g，3.3mmol，1.5eq)，加毕，搅拌下升温回流反应10min，使反应液溶清，趁热过滤，滤液搅拌降至室温，有大量白色固体析出，放置过夜，过滤，干燥，得到式(I)所示复合物白色固体1.08g，收率83.1％。其X-衍射和DSC图谱经研究比对，确定产物为A晶型。
实施例3
取(1.0g，2.2mmol)1,6-脱水-1-C-{4-氯-3-[(3-氟-4-乙氧苯基)甲基]苯基}-5-C-(羟甲基)-β-L-艾杜吡喃糖(按WO2012019496公开的方法制备)，于10ml异丙醇/水(v：v＝1:1)中，加毕，搅拌溶解。常温下加入L-脯氨酸(0.25g，2.2mmol，1.0eq)，加毕，搅拌下升温回流反应10min，使反应液溶清，趁热过滤，滤液搅拌降至室温，有大量白色固体析出，放置过夜，过滤，干燥，得到式(I)所示复合物白色固体1.10g，收率84.6％。该结晶样品的X-射线衍射谱图见图1。其X-衍射和DSC图谱经研究比对，确定产物为A晶型。
实施例4
取(1.0g，1.7mmol)式(I)所示复合物(按实施例1制备)加入到250ml单口瓶中，加入160ml水，加热溶清，继续回流10分钟，冷却，静置析晶，抽滤，干燥得灰白色固体336mg，收率为33.6％，该固体样品的X-射线衍射谱图见图3，显示无晶型特征吸收峰，DSC谱图见图4，在200℃以下未见熔融吸收峰。据此确定产物为无定型固体。
实施例5
取(1.0g，1.7mmol)式(I)所示复合物(按实施例1制备)加入到25ml单口瓶中，加入2ml乙醇，加热溶清，继续回流10分钟，冷却，静置析晶，抽滤，干燥得白色固体728mg，收率为72.8％。其X-衍射和DSC图谱经研究比对，确定产物为A晶型。
实施例6
取(1.0g，1.7mmol)式(I)所示复合物(按实施例1制备)加入到25ml单口瓶中，加入2ml甲醇，加热溶清，继续回流10分钟，冷却，静置析晶，抽滤，干燥得白色固体643mg，收率为64.3％。其X-衍射和DSC图谱经研究比对，确定产物为A晶型。
实施例7
取(1.0g，1.7mmol)式(I)所示复合物(按实施例1制备)加入到25ml单口瓶中，加入2ml 50％甲醇，加热溶清，继续回流10分钟，冷却，静置析晶，抽滤，干燥得白色固体602mg，收率为60.2％。该结晶样品的X-射线衍射和DSC谱图经研究比对，确定产物为A晶型。
实施例8
取(1.0g，1.7mmol)式(I)所示复合物(按实施例1制备)加入到25ml单口瓶中，加入2ml异丙醇，加热溶清，继续回流10分钟，冷却，静置析晶，抽滤，干燥得白色固体740mg，收率为74.0％。该结晶样品的X-射线衍射和DSC谱图经研究比对，确定产物为A晶型。
实施例9
取(1.0g，1.7mmol)式(I)所示复合物(按实施例1制备)加入到25ml单口瓶中，加入2ml 50％乙醇，加热溶清，继续回流10分钟，冷却，静置析晶，抽滤，干燥得白色固体595mg，收率为59.5％。该结晶样品的X-射线衍射和DSC谱图经研究比对，确定产物为A晶型。
实施例10
取(1.0g，1.7mmol)式(I)所示复合物(按实施例1制备)加入到25ml单口瓶中，加入2ml 95％乙醇，加热溶清，继续回流10分钟，冷却，静置析晶，抽滤，干燥得白色固体813mg，收率为81.3％。其X-衍射和DSC图谱经研究比对，确定产物为A晶型。
实施例11
取(1.0g，1.7mmol)式(I)所示复合物(按实施例1制备)加入到25ml单口瓶中，加入3ml乙醇/正己烷(3:1)，加热溶清，继续回流10分钟，冷却，静置析晶，抽滤，干燥得白色固体804mg，收率为80.4％。其X-衍射和DSC图谱经研究比对，确定产物为A晶型。
实施例12
取(1.0g，1.7mmol)式(I)所示复合物(按实施例1制备)于250ml单口瓶中，加入94ml 10％乙醇，加热溶清，继续回流10分钟，冷却，静置析晶，抽滤，干燥得白色固体338mg，收率为33.8％。其X-衍射和DSC图谱经研究比对，确定产物为无定形。
实施例13
将实施例1所得的A型结晶产物和实施例4制得的无定型的样品分别敞口平摊放置，考察在光照(4500Lux)，加热(40℃，60℃)，高湿(RH75％，RH90％)条件下样品的稳定性。考察取样时间为5天和10天，HPLC检测纯度见表1。
表1、式(I)所示复合物A型结晶和无定型样品的稳定性比较
Figure PCTCN2015089128-appb-000003
稳定性考察结果表明式(I)所示复合物A型结晶和无定型样品在敞口放置的条件下，经光照、高温和高湿条件下的稳定性比较发现，高湿对两者的影响不大，但是在光照、高温的条件下，A型结晶的稳定性显著好于无定型样品。
实施例14
将按实施例1方法制得的式(I)所示复合物A型结晶进行研磨、加热及压片处理，研究结果表明晶型稳定，详细的实验数据参见下表2。
表2.式(I)所示复合物A晶型特殊稳定性研究
Figure PCTCN2015089128-appb-000004
实施例15
按照CN104031098A制备例15相同的方法，将L-脯氨酸(0.23g,2mmol)溶解于1.2mL的90％乙醇/水中，将该溶液加热至微沸，再加入溶于4mL乙醇的1,6-脱水-1-C-{4-氯-3-[(3-氟-4-乙氧苯基)甲基]苯基}-5-C-(羟甲基)-β-L-艾杜吡喃糖(0.5mmol)的溶液。缓缓添加丙酮至总体积的10％，使所得溶液冷却至-20℃达2小时，在此期间会形成固体。使该溶液在室温下放置2天。使该容器离心，去除上清液。剩余的固体用正己烷洗涤，使该固体在真空下干燥，得到白色固体。HPLC分析显示在该白色结晶固体中1,6-脱水-1-C-{4-氯-3-[(3-氟-4-乙氧苯基)甲基]苯基}-5-C-(羟甲基)-β-L-艾杜吡喃糖与L-脯氨酸的摩尔比例约为0.46，其DSC图和TGA图分别如图5、图6所示。DSC图显示，所得固体在60.78℃、69.79℃以及105.90℃有三处吸热峰，这暗示该物质可能不太稳定，在较低温度下就有可能产生降解导致脯氨酸从共晶体中脱落。TGA图显示，该固体中脯氨酸失重为30.58％(1,6-脱水-1-C-{4-氯-3-[(3-氟-4-乙氧苯基)甲基]苯基}-5-C-(羟甲基)-β-L-艾杜吡喃糖与L-脯氨酸的比例为1：2时理论值为33.4％)。综合HPLC和DSC、TGA的分析结果，表明所得固体产物中1,6-脱水-1-C-{4-氯-3-[(3-氟-4-乙氧苯基)甲基]苯基}-5-C-(羟甲基)-β-L-艾杜吡喃糖与L-脯氨酸的比例为1：2，且所得产物稳定性较差。
实施例16
按照CN104031098A制备例16相同的方法，将L-脯氨酸 (0.23g,2mmol)溶解于1.2mL的90％乙醇/水中，将该溶液加热至微沸，再加入溶于4mL乙醇的1,6-脱水-1-C-{4-氯-3-[(3-氟-4-乙氧苯基)甲基]苯基}-5-C-(羟甲基)-β-L-艾杜吡喃糖(0.5mmol)的溶液。缓缓添加丙酮至总体积的5％，使所得溶液冷却至-20℃达3小时，在此期间会形成固体。使该溶液在室温下放置1.5天。使该容器离心，去除上清液。剩余的固体用正己烷洗涤，使该固体在真空下干燥，得到白色固体。HPLC分析显示在该白色结晶固体中1,6-脱水-1-C-{4-氯-3-[(3-氟-4-乙氧苯基)甲基]苯基}-5-C-(羟甲基)-β-L-艾杜吡喃糖与L-脯氨酸的摩尔比例约为0.54，其DSC图和TGA图分别如图7、图8所示。DSC图显示，所得固体在59.55℃、72.24℃以及105.49℃有三处吸热峰，这暗示该物质可能不太稳定，在较低温度下就有可能产生降解导致脯氨酸从共晶体中脱落。TGA图显示，该固体中脯氨酸失重为32.82％(1,6-脱水-1-C-{4-氯-3-[(3-氟-4-乙氧苯基)甲基]苯基}-5-C-(羟甲基)-β-L-艾杜吡喃糖时理论值为33.4％)。综合HPLC和DSC、TGA的分析结果，表明所得固体产物中1,6-脱水-1-C-{4-氯-3-[(3-氟-4-乙氧苯基)甲基]苯基}-5-C-(羟甲基)-β-L-艾杜吡喃糖与L-脯氨酸的比例为1：2，且所得产物稳定性较差。

Claims (9)

  1. 如式(I)所示复合物，或其一水合物，
    Figure PCTCN2015089128-appb-100001
  2. 式(I)所示复合物的A型结晶，所述结晶为一水合物结晶，其特征在于：使用Cu-Ka辐射，得到以2θ角度和晶面间距表示的X-射线粉末衍射图谱，所述结晶具有如图1所示的X-射线粉末衍射图谱，其中在约5.41(16.33)，7.69(11.49)，10.22(8.65)，12.04(7.35)，12.46(7.10)，14.42(6.14)，17.30(5.12)，18.79(4.72)，19.38(4.58)，20.24(4.38)，22.73(3.91)，24.58(3.62)，27.55(3.24)，28.82(3.10)和31.03(2.88)有特征峰。
  3. 一种根据权利要求1所述的如式(I)所示复合物或其一水合物的制备方法，包括将1，6-脱水-1-C-{4-氯-3-[(3-氟-4-乙氧苯基)甲基]苯基}-5-C-(羟甲基)-β-L-艾杜吡喃糖和L-脯氨酸共结晶的步骤，其中，所述共结晶加入的L-脯氨酸和1，6-脱水-1-C-{4-氯-3-[(3-氟-4-乙氧苯基)甲基]苯基}-5-C-(羟甲基)-β-L-艾杜吡喃糖的摩尔比例小于2：1，优选2：1至0.1：1，更优选1.5：1至0.5：1，最优选1.5：1至1：1。
  4. 根据权利要求3所述的制备方法，所述共结晶在溶剂中进行，所述溶剂选自有机溶剂或有机溶剂与水的混合溶剂；所述有机溶剂选自碳原子数小于等于6的醇类、酮类、酯类、醚类、烷烃、腈类的任意一种或几种；优选甲醇、乙醇、异丙醇、丙酮、乙酸乙酯、四氢呋喃、乙腈、正己烷；或甲醇/水、乙醇/水、异丙醇/水、乙醇/正己烷；其中最优选单一溶剂为乙醇，最优选的混合溶剂为乙醇/水。
  5. 一种根据权利要求2所述的式(I)所示复合物的A型结晶的 制备方法，所述制备方法包括下述步骤：
    1)将1，6-脱水-1-C-{4-氯-3-[(3-氟-4-乙氧苯基)甲基]苯基}-5-C-(羟甲基)-β-L-艾杜吡喃糖和L-脯氨酸加入溶剂中，使反应液溶清，冷却，析晶，所述溶剂选自有机溶剂或有机溶剂与水的混合溶剂；所述有机溶剂选自碳原子数小于等于6的醇类、酮类、酯类、醚类、烷烃、腈类的任意一种或几种；
    2)过滤结晶并洗涤，干燥；
    优选在步骤1中加入的L-脯氨酸和1，6-脱水-1-C-{4-氯-3-[(3-氟-4-乙氧苯基)甲基]苯基}-5-C-(羟甲基)-β-L-艾杜吡喃糖的摩尔比例小于2：1，更优选2：1至0.1：1，进一步优选1.5：1至0.5：1，最优选1.5：1至1：1。
  6. 根据权利要求5所述的制备方法，其特征在于在步骤1)中所述的溶剂为甲醇、乙醇、异丙醇、丙酮、乙酸乙酯、四氢呋喃、乙腈、正己烷；或甲醇/水、乙醇/水、异丙醇/水、乙醇/正己烷；其中最优选单一溶剂为乙醇，最优选的混合溶剂为乙醇/水。
  7. 根据权利要求5所述的制备方法，其中所述方法还包括将干燥所得结晶产物进一步重结晶的步骤，所述重结晶溶剂选自有机溶剂或有机溶剂与水的混合溶剂；所述有机溶剂选自碳原子数小于等于6的醇类、酮类、酯类、醚类、烷烃、腈类的任意一种或几种；优选甲醇、乙醇、异丙醇、丙酮、乙酸乙酯、四氢呋喃、乙腈、正己烷；或甲醇/水、乙醇/水、异丙醇/水、乙醇/正己烷；其中最优选单一溶剂为乙醇，最优选的混合溶剂为乙醇/水。
  8. 一种药物组合物，其含有根据权利要求1所述的如式(I)所示复合物或其一水合物或根据权利要求2所述的式(I)所示复合物的A型结晶以及药学上可接受的载体。
  9. 根据权利要求1所述的如式(I)所示复合物或其一水合物、或根据权利要求2所述的式(I)所示复合物的A型结晶或根据权利要求 8所述的药物组合物在制备治疗与钠-葡萄糖协同转运蛋白2有关的疾病的药物中的用途；所述疾病优选糖尿病。
PCT/CN2015/089128 2014-09-30 2015-09-08 一种钠-葡萄糖协同转运蛋白2抑制剂的l-脯氨酸复合物、其一水合物及晶体 Ceased WO2016050134A1 (zh)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2017512686A JP6761564B2 (ja) 2014-09-30 2015-09-08 ナトリウム・グルコース共輸送体２阻害薬のｌ−プロリン化合物、およびｌ−プロリン化合物の一水和物および結晶
US15/514,118 US10301344B2 (en) 2014-09-30 2015-09-08 L-proline complex of sodium-glucose cotransporter 2 inhibitor, monohydrate and crystal form thereof
BR112017005454A BR112017005454A2 (pt) 2014-09-30 2015-09-08 composto de l-prolina do inibidor 2 do cotransportador de sódio-glicose, e mono-hidrato e cristal do composto de l-prolina
EP15846001.4A EP3202772B1 (en) 2014-09-30 2015-09-08 Crystal of a complex of l-proline/sodium-glucose cotransporter 2 inhibitor
KR1020177009290A KR20170060035A (ko) 2014-09-30 2015-09-08 나트륨 글루코스 공동운반체 2 억제제의 ｌ- 프롤린 화합물, 및 ｌ- 프롤린 화합물의 모노하이드레이트 및 결정
ES15846001T ES2836099T3 (es) 2014-09-30 2015-09-08 Cristal de un complejo de L-prolina/inhibidor del cotransportador de sodio-glucosa tipo 2
CA2961819A CA2961819C (en) 2014-09-30 2015-09-08 L-proline compound of sodium-glucose cotransporter 2 inhibitor, and monohydrate and crystal of l-proline compound
CN201580008497.4A CN105992769B (zh) 2014-09-30 2015-09-08 一种钠-葡萄糖协同转运蛋白2抑制剂的l-脯氨酸复合物、其一水合物及晶体
PL15846001.4T PL3202772T3 (pl) 2014-09-30 2015-09-08 Kryształ kompleksu inhibitora l-proliny/glukozy sodowej 2

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410523436.9 2014-09-30
CN201410523436 2014-09-30

Publications (1)

Publication Number Publication Date
WO2016050134A1 true WO2016050134A1 (zh) 2016-04-07

Family

ID=55629417

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/089128 Ceased WO2016050134A1 (zh) 2014-09-30 2015-09-08 一种钠-葡萄糖协同转运蛋白2抑制剂的l-脯氨酸复合物、其一水合物及晶体

Country Status (13)

Country Link
US (1) US10301344B2 (zh)
EP (1) EP3202772B1 (zh)
JP (1) JP6761564B2 (zh)
KR (1) KR20170060035A (zh)
CN (1) CN105992769B (zh)
BR (1) BR112017005454A2 (zh)
CA (1) CA2961819C (zh)
ES (1) ES2836099T3 (zh)
HU (1) HUE052588T2 (zh)
PL (1) PL3202772T3 (zh)
PT (1) PT3202772T (zh)
TW (1) TWI680983B (zh)
WO (1) WO2016050134A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112375087A (zh) * 2020-11-27 2021-02-19 浙江天宇药业股份有限公司 一种脯氨酸恒格列净的合成方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118894894A (zh) * 2018-02-07 2024-11-05 里亚塔医药公司 新生霉素类似物与脯氨酸的共晶体形式

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102149717A (zh) * 2008-08-28 2011-08-10 辉瑞大药厂 二氧杂-双环[3.2.1]辛烷-2,3,4-三醇衍生物
CN102372722A (zh) * 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用
CN104017031A (zh) * 2014-06-21 2014-09-03 李友香 降血糖药物和组合物
CN104031098A (zh) * 2014-06-21 2014-09-10 李友香 降糖药物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011113915A1 (en) * 2010-03-17 2011-09-22 Katholieke Universiteit Leuven Storage of respiratory produce
KR20150048114A (ko) * 2012-07-11 2015-05-06 오시리스 쎄라퓨틱스, 인크. 공극형성된 연골 제품
US9145434B2 (en) * 2012-07-26 2015-09-29 Boehringer Ingelheim International Gmbh Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
FI2981269T3 (fi) * 2013-04-04 2023-09-27 Boehringer Ingelheim Vetmedica Gmbh Aineenvaihduntahäiriöiden hoito hevoseläimillä

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102149717A (zh) * 2008-08-28 2011-08-10 辉瑞大药厂 二氧杂-双环[3.2.1]辛烷-2,3,4-三醇衍生物
CN102372722A (zh) * 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用
CN104017031A (zh) * 2014-06-21 2014-09-03 李友香 降血糖药物和组合物
CN104031098A (zh) * 2014-06-21 2014-09-10 李友香 降糖药物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3202772A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112375087A (zh) * 2020-11-27 2021-02-19 浙江天宇药业股份有限公司 一种脯氨酸恒格列净的合成方法

Also Published As

Publication number Publication date
CA2961819A1 (en) 2016-04-07
CA2961819C (en) 2022-11-08
EP3202772A1 (en) 2017-08-09
TW201612188A (en) 2016-04-01
KR20170060035A (ko) 2017-05-31
EP3202772A4 (en) 2017-08-09
ES2836099T3 (es) 2021-06-24
CN105992769A (zh) 2016-10-05
JP6761564B2 (ja) 2020-09-30
JP2017530107A (ja) 2017-10-12
BR112017005454A2 (pt) 2017-12-12
HUE052588T2 (hu) 2021-05-28
PL3202772T3 (pl) 2021-02-22
EP3202772B1 (en) 2020-10-28
US10301344B2 (en) 2019-05-28
PT3202772T (pt) 2020-11-20
TWI680983B (zh) 2020-01-01
CN105992769B (zh) 2019-04-02
US20170298087A1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
TWI726030B (zh) 一種ｂｔｋ激酶抑制劑的結晶形式及其製備方法
CN105980390B (zh) 一种jak激酶抑制剂的硫酸氢盐的结晶形式及其制备方法
WO2014008794A1 (zh) 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法
WO2016124067A1 (zh) 一种周期素依赖性蛋白激酶抑制剂的羟乙基磺酸盐、其结晶形式及制备方法
JPWO2018117267A1 (ja) 置換ピペリジン化合物の塩
WO2018059429A1 (zh) 一种非溶剂化晶体及其制备方法与应用
CN101218220A (zh) 薁类化合物的胆碱盐结晶
WO2013132511A1 (en) Novel polymorph of lurasidone hydrochloride
WO2016169422A1 (zh) 一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法
WO2021004401A1 (zh) 一种btk激酶抑制剂关键中间体的晶型及其制备方法
CN107531744B (zh) 一种奥贝胆酸的新结晶形式及其制备方法
WO2016050134A1 (zh) 一种钠-葡萄糖协同转运蛋白2抑制剂的l-脯氨酸复合物、其一水合物及晶体
WO2016188444A1 (zh) 一种尿酸转运蛋白抑制剂的钠盐及其结晶形式
WO2018133823A1 (zh) 一种jak激酶抑制剂的硫酸氢盐的晶型及其制备方法
WO2018072742A1 (zh) 一种咪唑并异吲哚类衍生物的游离碱的结晶形式及其制备方法
WO2020073984A1 (zh) 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法
WO2019080865A1 (zh) 一种炔基吡啶类脯氨酰羟化酶抑制剂的晶型及其制备方法
WO2016110243A1 (zh) 一种酪氨酸激酶抑制剂的苹果酸盐的结晶形式及其制备方法
WO2017219994A1 (zh) 9-氨基甲基取代的四环素类化合物的晶型及其制备方法
WO2019011316A1 (zh) 一种btk激酶抑制剂的结晶形式及制备方法
WO2017041622A1 (zh) 一种雄性激素受体抑制剂的结晶形式及其制备方法
CN108026043A (zh) 一种萘环化合物的晶型
HK1227882B (zh) 一种钠-葡萄糖协同转运蛋白2抑制剂的l-脯氨酸复合物、其一水合物及晶体
WO2023222103A1 (zh) 一种三嗪二酮类衍生物的晶型及制备方法
HK1227882A1 (zh) 一种钠-葡萄糖协同转运蛋白2抑制剂的l-脯氨酸复合物、其一水合物及晶体

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15846001

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2017512686

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2961819

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 15514118

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017005454

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20177009290

Country of ref document: KR

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2015846001

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 112017005454

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170317